Picture of Bioventix logo

BVXP Bioventix News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedSmall CapHigh Flyer

REG-Bioventix Plc: Result of AGM <Origin Href="QuoteRef">BVXP.L</Origin>

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                                 Result of AGM                                 

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held
yesterday afternoon, all resolutions put to shareholders were duly passed.

For further information please contact:

Bioventix plc                                     Tel: 01252 728 001     
Peter Harrison           Chief Executive Officer                         
                                                                         
finnCap Ltd                                       Tel: 020 7220 0500     
Geoff Nash/Simon Hicks   Corporate Finance                               
Stephen Norcross         Corporate Broking                               

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



END



Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved

Recent news on Bioventix

See all news